Short-term daily price predictions for volatile clinical-stage biopharmaceutical equities like Neumora Therapeutics cannot be forecasted with certainty because valuations swing heavily based on live market sentiment, incoming news flow, and day-to-day trading liquidity. While 12-month average analyst price targets span higher expectations based on the remaining pipeline, immediate day-to-day movements remain highly unpredictable. Market participants tracking short-term horizons rely heavily on technical momentum indicators, intraday order book depth, and broader biotechnology sector trends rather than fixed daily prognostications.